Graphite Bio Inc

NASDAQ:GRPH  
2.28
-0.01 (-0.44%)
Products

Graphite Bio Announces U.S. FDA Fast Track Designation Granted To Gph101 For The Treatment Of Sickle Cell Disease

Published: 05/03/2022 12:33 GMT
Graphite Bio Inc (GRPH) - Graphite Bio Announces U.S. FDA Fast Track Designation Granted to Gph101 for the Treatment of Sickle Cell Disease.
Graphite Bio Announces U.S. FDA Fast Track Designation Granted to Gph101 for the Treatment of Sickle Cell Disease.
Graphite Bio Inc Says Gph101 is an Investigational Next-generation Gene-edited Therapy Designed to Potentially Provide a One-time Cure for Patients.